BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $9 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.5%

Neg 0% Neu 86.5% Pos 0%

BTIG analyst Jeet Mukherjee reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Buy and maintains $9 price target.

Comments

No comments yet. Be the first!